HomeCompareNODB vs ABBV

NODB vs ABBV: Dividend Comparison 2026

NODB yields 0.59% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.6K in total portfolio value
10 years
NODB
NODB
● Live price
0.59%
Share price
$67.99
Annual div
$0.40
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.8K
Annual income
$0.06
Full NODB calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NODB vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNODBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NODB + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NODB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NODB
Annual income on $10K today (after 15% tax)
$50.01/yr
After 10yr DRIP, annual income (after tax)
$0.05/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NODB + ABBV for your $10,000?

NODB: 50%ABBV: 50%
100% ABBV50/50100% NODB
Portfolio after 10yr
$61.1K
Annual income
$12,385.91/yr
Blended yield
20.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NODB
No analyst data
Altman Z
-0.6
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NODB buys
0
ABBV buys
0
No recent congressional trades found for NODB or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNODBABBV
Forward yield0.59%3.06%
Annual dividend / share$0.40$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$19.8K$102.3K
Annual income after 10y$0.06$24,771.77
Total dividends collected$59.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NODB vs ABBV ($10,000, DRIP)

YearNODB PortfolioNODB Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,729$29.42$11,550$430.00$821.00ABBV
2$11,495$14.75$13,472$627.96$2.0KABBV
3$12,307$7.38$15,906$926.08$3.6KABBV
4$13,172$3.69$19,071$1,382.55$5.9KABBV
5$14,096$1.85$23,302$2,095.81$9.2KABBV
6$15,084$0.92$29,150$3,237.93$14.1KABBV
7$16,140$0.46$37,536$5,121.41$21.4KABBV
8$17,270$0.23$50,079$8,338.38$32.8KABBV
9$18,480$0.12$69,753$14,065.80$51.3KABBV
10$19,773$0.06$102,337$24,771.77$82.6KABBV

NODB vs ABBV: Complete Analysis 2026

NODBStock

North Dallas Bank & Trust Co. provides personal and business banking products and services in Texas. The company offers checking and savings accounts; certificate of deposits and individual retirement accounts; vehicle, personal, overdraft protection, home equity, home improvement, and construction and residential lot loans, as well as home equity line of credit; debit and credit cards; mortgage loans; and online and mobile banking services. It also provides business lines of credit, equipment financing, commercial real estate, and interim construction loans, as well as healthcare financing and physician services; and treasury services, such as payables, receivables, information reporting, liquidity management, and fraud mitigation services. In addition, the company offers investment management, trust, retirement, and financial planning services. It operates banking centers in Addison, Dallas, Frisco, Las Colinas, and Plano. The company was incorporated in 1961 and is based in Dallas, Texas.

Full NODB Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NODB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NODB vs SCHDNODB vs JEPINODB vs ONODB vs KONODB vs MAINNODB vs JNJNODB vs MRKNODB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.